毛豆
Lv1
40 积分
2022-02-21 加入
-
免疫检查点抑制剂治疗恶性肿瘤的PET_CT评价专家共识(2020版)
1个月前
已完结
-
[Cancer statistics in China, 2016]
1年前
已完结
-
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
1年前
已完结
-
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
1年前
已完结
-
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
1年前
已完结
-
Abstract LB113: Genomic classification to refine prognosis in clear cell renal cell carcinoma
1年前
已关闭
-
Bladder Cancer
1年前
已完结
-
Olaparib for Metastatic Castration-Resistant Prostate Cancer
1年前
已完结
-
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
1年前
已完结
-
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
1年前
已完结